8-K Announcements
6Material company update
Jun 10, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 9, 2026·SEC
enGene Holdings Inc.(ENGN)Earnings, Financials & Key Ratios
ENGN•NASDAQ
Price updated Jun 11, 2026
AboutenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Show more
- Revenue$0
- EBITDA-$123M-97.9%
- Net Income-$117M-112.7%
- EPS (Diluted)-2.29-56.8%
- ROE-53.28%-66.7%
- ROIC-67.43%+9.5%
- Debt/Equity0.19+106.5%
- Interest Coverage-38.18-104.0%
ENGN Key Insights
enGene Holdings Inc. (ENGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 14.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ENGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ENGN Price & Volume
enGene Holdings Inc. (ENGN) stock price & volume — 10-year historical chart
Loading chart...
ENGN Growth Metrics
enGene Holdings Inc. (ENGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-77.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM18.42%
Return on Capital
10 Years-27.01%
5 Years-27.01%
3 Years-36.04%
Last Year-50.69%
ENGN Recent Earnings
enGene Holdings Inc. (ENGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (40%)
Q2 2026Latest
Mar 9, 2026EPS
$0.44
Est $0.55
+20.0%
Revenue
—
Q4 2025
Dec 22, 2025EPS
$0.73
Est $0.57
-28.8%
Revenue
—
Q4 2025
Sep 11, 2025EPS
$0.57
Est $0.50
-14.5%
Revenue
—
Q3 2025
Jun 12, 2025EPS
$0.51
Est $0.50
-2.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 9, 2026 | $0.44vs $0.55+20.0% | — |
| Q4 2025 | Dec 22, 2025 | $0.73vs $0.57-28.8% | — |
| Q4 2025 | Sep 11, 2025 | $0.57vs $0.50-14.5% | — |
| Q3 2025 | Jun 12, 2025 | $0.51vs $0.50-2.6% | — |
Based on last 12 quarters of dataView full earnings history →
ENGN Peer Comparison
enGene Holdings Inc. (ENGN) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 290.45M | 2.66 | -1.32 | -70.79% | 0.09 | |||
 KRYS | 9.48B | 321.55 | 47.01 | 33.94% | 53.92% | 19.25% | 0.01 | |
 TGTX | 7.36B | 48.05 | 17.35 | 87.32% | 65.95% | 87.36% | 0.40 | |
 JANX | 833.05M | 13.66 | -7.46 | -5.55% | -5.3% | -11.85% | 0.02 | |
 FATE | 229.62M | 1.97 | -1.71 | -51.24% | -20.57% | -58.89% | 0.38 | |
 NTLA | 1.39B | 12.35 | -3.24 | 16.92% | -5.97% | -57.27% | 0.14 | |
 EDIT | 238.89M | 2.44 | -1.36 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CRSP | 4.84B | 50.23 | -7.76 | -89.97% | -138.57% | -30.88% | 0.21 |
Compare ENGN vs Peers
enGene Holdings Inc. (ENGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENGN Income Statement
enGene Holdings Inc. (ENGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Oct'21 | Oct'22 | Oct'23 | Oct'24 | Oct'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 189K |
COGS % of Revenue | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -189K▲ 0% |
Gross Margin % | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - |
Operating Expenses | 15.87M | 19.43M | 26.06M | 62.3M | 123.17M | 127.55M |
OpEx % of Revenue | - | - | - | - | - | - |
Selling, General & Admin | 3.15M | 3.26M | 8.47M | 23.98M | 28.68M | 31.61M |
SG&A % of Revenue | - | - | - | - | - | - |
Research & Development | 12.46M | 15.47M | 16.46M | 38.31M | 94.48M | 96.76M |
R&D % of Revenue | - | - | - | - | - | - |
Other Operating Expenses | 253K | 700K | 1.13M | 0 | 0 | 440K |
Operating Income | -15.87M▲ 0% | -19.43M▼ 22.4% | -26.06M▼ 34.1% | -62.3M▼ 139.1% | -123.17M▼ 97.7% | -127.74M▲ 0% |
Operating Margin % | - | - | - | - | - | - |
Operating Income Growth % | - | -22.41% | -34.14% | -139.05% | -97.71% | - |
EBITDA | -15.6M | -19.19M | -25.89M | -61.97M | -122.66M | -127.14M |
EBITDA Margin % | - | - | - | - | - | - |
EBITDA Growth % | - | -23.02% | -34.89% | -139.42% | -97.92% | -63.44% |
D&A (Non-Cash Add-back) | 272K | 238K | 175K | 323K | 509K | 596K |
EBIT | -18.42M | -23.02M | -94.95M | -52.36M | -114.31M | -119.48M |
Net Interest Income | -5M | -1.29M | -3.84M | 7.62M | 6.43M | 6.46M |
Interest Income | 25K | 129K | 1.12M | 10.41M | 9.43M | 9.44M |
Interest Expense | 5.02M | 1.42M | 4.95M | 2.8M | 2.99M | 2.97M |
Other Income/Expense | -7.57M | -5.01M | -73.84M | 7.14M | 5.86M | 5.28M |
Pretax Income | -23.44M▲ 0% | -24.44M▼ 4.3% | -99.9M▼ 308.8% | -55.16M▲ 44.8% | -117.3M▼ 112.7% | -122.46M▲ 0% |
Pretax Margin % | - | - | - | - | - | - |
Income Tax | 0 | 22K | 17K | -19K | 0 | -18K |
Effective Tax Rate % | 0% | -0.09% | -0.02% | 0.03% | 0% | 0.01% |
Net Income | -23.44M▲ 0% | -24.46M▼ 4.4% | -99.92M▼ 308.5% | -55.14M▲ 44.8% | -117.3M▼ 112.7% | -122.44M▲ 0% |
Net Margin % | - | - | - | - | - | - |
Net Income Growth % | - | -4.36% | -308.46% | 44.81% | -112.73% | -77.33% |
Net Income (Continuing) | -23.44M | -24.46M | -99.92M | -55.14M | -117.3M | -122.44M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.01▲ 0% | 0.00▲ 113.3% | -4.24▼ 223257.9% | -1.46▲ 65.6% | -2.29▼ 56.8% | -1.82▲ 0% |
EPS Growth % | - | 113.29% | - | 65.57% | -56.85% | 18.42% |
EPS (Basic) | -0.01 | 0.00 | -4.24 | -1.46 | -2.29 | - |
Diluted Shares Outstanding | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M | 67.26M |
Basic Shares Outstanding | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M | 67.26M |
Dividend Payout Ratio | - | - | - | - | - | - |
ENGN Balance Sheet
enGene Holdings Inc. (ENGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Oct'21 | Oct'22 | Oct'23 | Oct'24 | Oct'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 1.57M | 511.8K | 85.44M | 247.36M | 201.39M | 289.22M |
Cash & Short-Term Investments | 1.07M | 314.15K | 81.6M | 238.4M | 193.81M | 275.95M |
Cash Only | 1.07M | 314.15K | 81.52M | 173M | 50.15M | 36.61M |
Short-Term Investments | 0 | 0 | 76K | 65.4M | 143.66M | 239.34M |
Accounts Receivable | 0 | 0 | 2.34M | 1.03M | 2.23M | 1.2M |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 1.5M | 7.93M | 5.35M | 12.07M |
Total Non-Current Assets | 129.88M | 131.53M | 1.52M | 63.81M | 20.08M | 47.9M |
Property, Plant & Equipment | 0 | 0 | 589K | 2.91M | 10.19M | 9.91M |
Fixed Asset Turnover | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 129.67M | 131.53M | 70K | 59.53M | 8.52M | 102.24M |
Other Non-Current Assets | 209.05K | 0 | 860K | 1.37M | 1.36M | 1.39M |
Total Assets | 131.45M▲ 0% | 132.04M▲ 0.5% | 86.96M▼ 34.1% | 311.17M▲ 257.8% | 221.47M▼ 28.8% | 337.11M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.00x |
Asset Growth % | - | 0.45% | -34.14% | 257.84% | -28.83% | -21.43% |
Total Current Liabilities | 327.45K | 893.51K | 5.26M | 14.66M | 31.98M | 24.61M |
Accounts Payable | 0 | 0 | 1.16M | 1.41M | 6.69M | 2.44M |
Days Payables Outstanding | - | - | - | - | - | 6.31K |
Short-Term Debt | 0 | 0 | 562K | 1.12M | 10.02M | 2.51M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 327.45K | 893.51K | 2.69M | 8.65M | 11.2M | 19.67M |
Current Ratio | 4.79x | 0.57x | 16.25x | 16.87x | 6.30x | 11.75x |
Quick Ratio | 4.79x | 0.57x | 16.25x | 16.87x | 6.30x | 11.75x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 3.73M | 3.73M | 9.22M | 23.9M | 21.78M | 30.96M |
Long-Term Debt | 0 | 0 | 9.22M | 22.47M | 15.32M | 24.74M |
Capital Lease Obligations | 0 | 0 | 0 | 1.43M | 6.46M | 20.75M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 3.73M | 0 | 0 | 0 | 0 |
Total Liabilities | 4.05M | 4.62M | 14.47M | 38.56M | 53.76M | 55.57M |
Total Debt | 0 | 0 | 9.78M | 25.02M | 31.8M | 33.46M |
Net Debt | -1.07M | -314.15K | -71.74M | -147.98M | -18.36M | -3.15M |
Debt / Equity | - | - | 0.13x | 0.09x | 0.19x | 0.12x |
Debt / EBITDA | - | - | - | - | - | -0.26x |
Net Debt / EBITDA | - | - | - | - | - | 0.02x |
Interest Coverage | -3.67x | -16.17x | -19.17x | -18.71x | -38.18x | -40.18x |
Total Equity | 127.39M▲ 0% | 127.42M▲ 0.0% | 72.49M▼ 43.1% | 272.61M▲ 276.1% | 167.71M▼ 38.5% | 281.55M▲ 0% |
Equity Growth % | - | 0.02% | -43.11% | 276.09% | -38.48% | -45.17% |
Book Value per Share | 8.06 | 8.06 | 3.08 | 6.11 | 3.28 | 4.19 |
Total Shareholders' Equity | 127.39M | 127.42M | 72.49M | 272.61M | 167.71M | 281.55M |
Common Stock | 129.67M | 131.53M | 259.37M | 509.81M | 513.28M | 631.99M |
Retained Earnings | -2.28M | -4.11M | -199.59M | -254.73M | -372.03M | -401.78M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -1.02M | -1.42M | -888K | -842K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
ENGN Cash Flow Statement
enGene Holdings Inc. (ENGN) cash flow — operating, investing & free cash flow history
| Metric | Oct'21 | Oct'22 | Oct'23 | Oct'24 | Oct'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -15.98M | -17.59M | -24.74M | -48.28M | -99.24M | -102.45M |
Operating CF Margin % | - | - | - | - | - | - |
Operating CF Growth % | - | -10.06% | -40.65% | -95.13% | -105.54% | -359.05% |
Net Income | -23.44M | -24.46M | -99.92M | -55.14M | -117.3M | -122.44M |
Depreciation & Amortization | 272K | 238K | 175K | 323K | 509K | 596K |
Stock-Based Compensation | 435K | 116K | 3.45M | 5.32M | 9.65M | 10.64M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 7.79M | 4.34M | 72.07M | 1.12M | -1.83M | -1.05M |
Working Capital Changes | -1.04M | 2.17M | -517K | 95K | 9.74M | 9.8M |
Change in Receivables | 295K | 143K | -1.01M | 2.01M | -595K | -768K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 110K | -197K | 373K | 474K | 4.94M | -454K |
Cash from Investing | -247K | -153K | -318K | -125.95M | -25.14M | -66.47M |
Capital Expenditures | -248K | -153K | -318K | -925K | -1.49M | -1.34M |
CapEx % of Revenue | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 1K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 22.52M | 27.97M | 86.15M | 265.72M | 1.52M | 143.18M |
Debt Issued (Net) | 7.07M | 28.39M | 33.27M | 13.05M | -699K | 633K |
Equity Issued (Net) | 15.6M | 12K | 56.89M | 260.15M | 2.22M | 142.55M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -144K | -423K | -4.01M | -7.49M | 0 | 0 |
Net Change in Cash | 6.39M▲ 0% | 9.42M▲ 47.3% | 61.09M▲ 548.7% | 91.48M▲ 49.8% | -122.85M▼ 234.3% | -25.73M▲ 0% |
Free Cash Flow | -16.23M▲ 0% | -17.75M▼ 9.3% | -25.06M▼ 41.2% | -49.21M▼ 96.3% | -100.72M▼ 104.7% | -103.78M▲ 0% |
FCF Margin % | - | - | - | - | - | - |
FCF Growth % | - | -9.32% | -41.23% | -96.34% | -104.7% | -54.16% |
FCF per Share | -1.03 | -1.12 | -1.06 | -1.10 | -1.97 | -1.54 |
FCF Conversion (FCF/Net Income) | 0.68x | 0.72x | 0.25x | 0.88x | 0.85x | 0.85x |
Interest Paid | 0 | 615K | 1.4M | 1.93M | 2.29M | 2.3M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
ENGN Key Ratios
enGene Holdings Inc. (ENGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -19.2% | -99.96% | -31.96% | -53.28% | -55.83% |
| Return on Invested Capital (ROIC) | -11.5% | -30.57% | -74.53% | -67.43% | -46.6% |
| Debt / Equity | - | 0.13x | 0.09x | 0.19x | 0.12x |
| Interest Coverage | -16.17x | -19.17x | -18.71x | -38.18x | -40.18x |
| FCF Conversion | 0.72x | 0.25x | 0.88x | 0.85x | 0.85x |
Related:ENGN Dividend History·ENGN Revenue History·ENGN Price History·ENGN P/E History·ENGN Financial Ratios·ENGN Institutional Holders
ENGN SEC Filings & Documents
enGene Holdings Inc. (ENGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
ENGN Frequently Asked Questions
enGene Holdings Inc. (ENGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
enGene Holdings Inc. (ENGN) grew revenue by 0.0% over the past year. Growth has been modest.
enGene Holdings Inc. (ENGN) reported a net loss of $122.4M for fiscal year 2025.
Dividend & Returns
enGene Holdings Inc. (ENGN) has a return on equity (ROE) of -53.3%. Negative ROE indicates the company is unprofitable.
enGene Holdings Inc. (ENGN) had negative free cash flow of $103.8M in fiscal year 2025, likely due to heavy capital investments.